ANRO

2.44

1.24% 0.03

Handel nachbörslich: 2.56 0.12 +4.92%

Alto Neuroscience Inc (ANRO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$2.41

Offen:

$2.41

24-Stunden-Volumen:

171.69K

Relative Volume:

0.56

Marktkapitalisierung:

$62.81M

Einnahmen:

Nettoeinkommen (Verlust:

$-49.81M

KGV:

-1.1317

EPS:

-2.156

Netto-Cashflow:

$-42.93M

1W Leistung:

+7.96%

1M Leistung:

+7.49%

6M Leistung:

-39.15%

1J Leistung:

-84.32%

1-Tages-Spanne:

$2.31

$2.46

1-Wochen-Bereich:

$2.20

$2.46

52-Wochen-Spanne:

$1.60

$17.55

Alto Neuroscience Inc Stock (ANRO) Company Profile

Firmenname

Alto Neuroscience Inc

Sektor

Healthcare (1157)

Branche

Biotechnology (664)

Telefon

773-255-5012

Adresse

650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ANRO's Discussions on Twitter

Vergleichen Sie ANRO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANRO Alto Neuroscience Inc	2.44	62.81M	0	-49.81M	-42.93M	-2.156
VRTX Vertex Pharmaceuticals Inc	503.50	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	568.91	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	629.51	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	257.19	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.77	24.70B	3.81B	-644.79M	-669.77M	-6.24

Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-23	Herabstufung	Rodman & Renshaw	Buy → Neutral
2024-10-23	Herabstufung	Wedbush	Outperform → Neutral
2024-09-03	Eingeleitet	Wedbush	Outperform
2024-02-27	Eingeleitet	Jefferies	Buy
2024-02-27	Eingeleitet	Robert W. Baird	Outperform
2024-02-27	Eingeleitet	Stifel	Buy
2024-02-27	Eingeleitet	TD Cowen	Outperform
2024-02-27	Eingeleitet	William Blair	Outperform

Alle ansehen

Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten

Apr 28, 2025

Alto Neuroscience presents new data at Society of Biological Psychiatry meeting - TipRanks

Apr 28, 2025

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire

Apr 28, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 22, 2025

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire

Apr 22, 2025

Apr 18, 2025

Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40 - Defense World

Apr 18, 2025

Apr 17, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 17, 2025

Apr 15, 2025

Wellington Management Group LLP Has $326,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World

Apr 15, 2025

Apr 11, 2025

Analysts Set Expectations for ANRO Q1 Earnings - Defense World

Apr 11, 2025

Apr 08, 2025

Alto Neuroscience initiated with a Buy at H.C. Wainwright - Yahoo Finance

Apr 08, 2025

Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at HC Wainwright - Defense World

Apr 08, 2025

Apr 07, 2025

HC Wainwright & Co. Initiates Coverage of Alto Neuroscience (ANRO) with Buy Recommendation - Nasdaq

Apr 07, 2025

Apr 01, 2025

Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World

Apr 01, 2025

Mar 30, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 30, 2025

Mar 28, 2025

ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia

Mar 28, 2025

Mar 24, 2025

William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World

Mar 23, 2025

Mar 21, 2025

Alto Neuroscience says its funded through 2028 - Green Market Report

Mar 21, 2025

Mar 20, 2025

ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq

Mar 20, 2025